Evidence map›Paper›PMID 36816040›Full record

ArticleFrontiers in genetics2023

Prognosis and personalized medicine prediction by integrated whole exome and transcriptome sequencing of hepatocellular carcinoma.

Debao Li, Lei Lei, Jinsong Wang, Bo Tang, Jiuling Wang, Rui Dong, Wenjiong Shi, Guo Liu, Tingting Zhao, Yuzhang Wu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Debao LiDepartment of Immunology, Medical College of Qingdao University, Qingdao, Shandong, China.
Lei LeiDepartment of Ophthalmology, Airforce Hospital, Chengdu, Sichuan, China.
Jinsong WangInstitute of Immunology, PLA, Army Medical University, Chongqing, China.
Bo TangChongqing International Institute for Immunology, Chongqing, China.
Jiuling WangInstitute of Immunology, PLA, Army Medical University, Chongqing, China.
Rui DongChongqing International Institute for Immunology, Chongqing, China.
Wenjiong ShiChongqing International Institute for Immunology, Chongqing, China.
Guo LiuQionglai Hospital of Traditional Chinese Medicine, Qionglai, Sichuan, China.
Tingting ZhaoChongqing International Institute for Immunology, Chongqing, China.
Yuzhang WuDepartment of Immunology, Medical College of Qingdao University, Qingdao, Shandong, China.
Yi ZhangChongqing International Institute for Immunology, Chongqing, China.
Army Medical University · CNChongqing University of Technology · CNPeople 's Liberation Army 451 Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a clinically and genetically heterogeneous disease. To better describe the clinical value of the main driver gene mutations of HCC, we analyzed the whole exome sequencing data of 125 patients, and combined with the mutation data in the public database, 14 main mutant genes were identified. And we explored the correlation between the main mutation genes and clinical features. Consistent with the results of previous data, we found that

Indexed as

hepatocellular carcinomaprognostic modelRNA sequencingTP53whole exome sequencing

Identifiers

PMID36816040
PMCPMC9932713
OpenAlexW4318998747

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.